Business Context and Reporting Period
This Form 8-K filing by Processa Pharmaceuticals, Inc. (PCSA) reports on the results of the Annual Meeting of Shareholders held on June 8, 2021. The report was filed on June 10, 2021.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document focuses exclusively on corporate governance and shareholder voting outcomes.
Material Changes and Voting Results
Shareholders voted on five proposals at the Annual Meeting. The results were as follows:
- Director Elections: All five nominees (Dr. David Young, Dr. Khalid Islam, Geraldine Pannu, Virgil Thompson, and Justin Yorke) were elected. While all received majority support, the number of "Against" votes varied, ranging from 7,905 for Dr. Young to 167,824 for Justin Yorke.
- Executive Compensation (Say-on-Pay): The advisory vote on executive compensation was approved with 11,011,750 votes "For" and 7,831 "Against."
- Compensation Vote Frequency: Shareholders voted to conduct the advisory vote on executive compensation annually (10,186,391 votes for 1 year).
- Incentive Plan Amendment: The proposal to increase the number of shares available under the 2019 Omnibus Incentive Plan by 2,500,000 was approved with 10,509,052 votes "For."
- Auditor Ratification: The appointment of BD & Company Inc. as the independent registered public accounting firm for 2021 was ratified with 12,467,390 votes "For."
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the total number of shares outstanding and the percentage of shares represented by the "Against" votes for directors, particularly Justin Yorke, to assess shareholder sentiment.
- Confirm the impact of the 2,500,000 share increase to the 2019 Omnibus Incentive Plan on potential future dilution.
- Review the full proxy statement for details on the specific compensation packages approved in the Say-on-Pay vote.
- Check subsequent filings for the company's financial performance, as this 8-K contains no financial data.